Halia Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Utah, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3900 N Traverse Mountain Blvd Ste 100, L...Phone Number
(385) 355-4315Website
www.haliatx.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
2
1
1
1
About Halia Therapeutics
Halia Therapeutics is discovering and developing novel therapeutics to improve the lives of patients with inflammatory disorders and neurological diseases. Halia scientists have made fundamental discoveries of inflammatory pathways associated with disease progression, and the company applies this knowledge to identify novel targets and discover new drug candidates to resolve the underlying causes of inflammation that drive disease. Halia is advancing a pipeline of innovative medicines that resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses. Halia is headquartered in Lehi, Utah.Explore more
Halia Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Halia Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Halia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Halia Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Halia Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Halia Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Halia Therapeutics launches new products
Check if Halia Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Halia Therapeutics recently announced quarterly report
Check out if Halia Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Halia Therapeutics
Compare insights from companies similar to Halia Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Halia Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Halia Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Halia Therapeutics.
Halia Therapeutics financials insights
Gather financial insights about Halia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$8M
2022
Series B
$12.2M
2024
Series C
$30M
2025
Private Equity
$337K
Halia Therapeutics Tech Stack
A closer look at the technologies used by Halia Therapeutics
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Halia Therapeutics News & Media
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 LEHI, Utah, June 15, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ofirnoflast (HT-6184) for the treatment of adult paHalia Therapeutics to Participate in Jefferies 2026 Global Healthcare Conference
LEHI, Utah, May 28, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., The Genetic Resilience Company™, a clinical-stage biopharmaceutical company advancing first-in-class inflammation therapies anchored in protective human genetics, today announced that the Company will participate in the...Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board
Industry leaders join at a pivotal moment as company advances HT-6184 toward a pivotal trial in MDS and prepares Phase 2a initiation for HT-4253 in Alzheimer's disease LEHI, Utah, May 19, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., The Genetic Resilience Company™, a clinical-stage...Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology leader and oncology drug-development executive, joins...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Halia Therapeutics
Sign Up For FreeTo access detailed company insights
Halia Therapeutics is discovering and developing novel therapeutics to improve the lives of patients with inflammatory disorders and neurological diseases. Halia scientists have made fundamental discoveries of inflammatory pathways associated with disease progression, and the company applies this knowledge to identify novel targets and discover new... Read More
